137 related articles for article (PubMed ID: 37150813)
1. Gene expression profiling and multiplex immunofluorescence analysis of bullous pemphigoid immune-related adverse event reveal upregulation of toll-like receptor 4/complement-induced innate immune response and increased density of T
Marques-Piubelli ML; Seervai RNH; Mudaliar KM; Ma W; Milton DR; Wang J; Muhlbauer A; Parra ER; Solis LM; Nagarajan P; Speiser J; Hudgens C; Cho WC; Aung PP; Patel A; Pacha O; Nelson KC; Tetzlaff MT; Amaria RN; Torres-Cabala CA; Prieto VG; Wistuba II; Curry JL
J Cutan Pathol; 2023 Jul; 50(7):661-673. PubMed ID: 37150813
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of lichenoid dermatitis immune-related adverse event from immune checkpoint inhibitors reveals increased CD14
Curry JL; Reuben A; Szczepaniak-Sloane R; Ning J; Milton DR; Lee CH; Hudgens C; George S; Torres-Cabala C; Johnson D; Subramanya S; Wargo JA; Mudaliar K; Wistuba II; Prieto VG; Diab A; Tetzlaff MT
J Cutan Pathol; 2019 Sep; 46(9):627-636. PubMed ID: 30883858
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint inhibitor-associated bullous cutaneous immune-related adverse events: a multicentre observational study.
Kawsar A; Edwards C; Patel P; Heywood RM; Gupta A; Mann J; Harland C; Heelan K; Larkin J; Lorigan P; Harwood CA; Matin RN; Fearfield L
Br J Dermatol; 2022 Dec; 187(6):981-987. PubMed ID: 35976170
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of toll-like receptors 2, 4, and 9 expressions in pemphigus and bullous pemphigoid lesions.
Sun XK; Chen JF; Shen H
Arch Dermatol Res; 2016 Aug; 308(6):429-36. PubMed ID: 27221282
[TBL] [Abstract][Full Text] [Related]
5. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid.
Le Jan S; Plée J; Vallerand D; Dupont A; Delanez E; Durlach A; Jackson PL; Edwin Blalock J; Bernard P; Antonicelli F
J Invest Dermatol; 2014 Dec; 134(12):2908-2917. PubMed ID: 24945093
[TBL] [Abstract][Full Text] [Related]
6. Differential expression of C5aR1 and C5aR2 in innate and adaptive immune cells located in early skin lesions of bullous pemphigoid patients.
Emtenani S; Holtsche MM; Stahlkopf R; Seiler DL; Burn T; Liu H; Parker M; Yilmaz K; Dikmen HO; Lang MH; Sadik CD; Karsten CM; van Beek N; Ludwig RJ; Köhl J; Schmidt E
Front Immunol; 2022; 13():942493. PubMed ID: 36466856
[TBL] [Abstract][Full Text] [Related]
7. Childhood bullous pemphigoid: a clinicopathologic study and review of the literature.
Fisler RE; Saeb M; Liang MG; Howard RM; McKee PH
Am J Dermatopathol; 2003 Jun; 25(3):183-9. PubMed ID: 12775979
[TBL] [Abstract][Full Text] [Related]
8. CCL18 is expressed in patients with bullous pemphigoid and parallels disease course.
Günther C; Carballido-Perrig N; Kopp T; Carballido JM; Pfeiffer C
Br J Dermatol; 2009 Apr; 160(4):747-55. PubMed ID: 19120345
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous Toxicities in the Setting of Immune Checkpoint Blockade:: The Era of Oncodermatopathology.
Curry JL; Chon SY; Marques-Piubelli ML; Chu EY
Surg Pathol Clin; 2021 Jun; 14(2):209-224. PubMed ID: 34023101
[TBL] [Abstract][Full Text] [Related]
10. Bullous pemphigoid autoantibodies directly induce blister formation without complement activation.
Ujiie H; Sasaoka T; Izumi K; Nishie W; Shinkuma S; Natsuga K; Nakamura H; Shibaki A; Shimizu H
J Immunol; 2014 Nov; 193(9):4415-28. PubMed ID: 25261486
[TBL] [Abstract][Full Text] [Related]
11. Bullous pemphigoid: etiology, pathogenesis, and inducing factors: facts and controversies.
Lo Schiavo A; Ruocco E; Brancaccio G; Caccavale S; Ruocco V; Wolf R
Clin Dermatol; 2013; 31(4):391-399. PubMed ID: 23806156
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
[TBL] [Abstract][Full Text] [Related]
13. Concomitant nivolumab-associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma.
Khazaeli M; Grover R; Pei S
J Cutan Pathol; 2023 Jun; 50(6):520-523. PubMed ID: 36601731
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for the Development of Bullous Pemphigoid in US Patients Receiving Immune Checkpoint Inhibitors.
Said JT; Liu M; Talia J; Singer SB; Semenov YR; Wei EX; Mostaghimi A; Nelson CA; Giobbie-Hurder A; LeBoeuf NR
JAMA Dermatol; 2022 May; 158(5):552-557. PubMed ID: 35416925
[TBL] [Abstract][Full Text] [Related]
15. Characteristic Pattern of IL-17RA, IL-17RB, and IL-17RC in Monocytes/Macrophages and Mast Cells From Patients With Bullous Pemphigoid.
Nesmond S; Muller C; Le Naour R; Viguier M; Bernard P; Antonicelli F; Le Jan S
Front Immunol; 2019; 10():2107. PubMed ID: 31572359
[TBL] [Abstract][Full Text] [Related]
16. Detection of elevated levels of IL-4, IL-6, and IL-10 in blister fluid of bullous pemphigoid.
Schmidt E; Bastian B; Dummer R; Tony HP; Bröcker EB; Zillikens D
Arch Dermatol Res; 1996 Jun; 288(7):353-7. PubMed ID: 8818181
[TBL] [Abstract][Full Text] [Related]
17. Eosinophil localization to the basement membrane zone is autoantibody- and complement-dependent in a human cryosection model of bullous pemphigoid.
Messingham KN; Wang JW; Holahan HM; Srikantha R; Aust SC; Fairley JA
Exp Dermatol; 2016 Jan; 25(1):50-5. PubMed ID: 26475989
[TBL] [Abstract][Full Text] [Related]
18. Nivolumab-induced localized genital bullous pemphigoid in a 60-year-old male.
Alvarado SM; Weston G; Murphy MJ; Stewart CL
J Cutan Pathol; 2022 May; 49(5):468-471. PubMed ID: 34881446
[TBL] [Abstract][Full Text] [Related]
19. IgG4, complement, and the mechanisms of blister formation in pemphigus and bullous pemphigoid.
Dainichi T; Chow Z; Kabashima K
J Dermatol Sci; 2017 Dec; 88(3):265-270. PubMed ID: 28747266
[TBL] [Abstract][Full Text] [Related]
20. Concominant bullous pemphigoid and cutaneous Crohn disease.
Cobb CBC; Caravaglio JV; Qureshi AA; Robinson-Bostom L
J Cutan Pathol; 2022 Jun; 49(6):579-583. PubMed ID: 35094410
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
